LBT Innovations Limited
LBT Innovations Limited (ASX: LBT) designs AI-powered automated microbiology culture plate reading instruments (APAS Independence) for pharmaceutical environmental monitoring and clinical laboratories globally, commercialized under the Clever Culture Systems brand.
- Company typePublic
- Founded2012
- HeadquartersAdelaide, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What LBT Innovations Limited does
LBT Innovations Limited is a publicly listed Australian company (ASX: LBT) that designs and commercializes AI-driven imaging technology for automated analysis of microbiology culture plates. Its core product, the APAS Independence, is an FDA-cleared in-vitro diagnostic instrument that uses computer vision to image, interpret, and report microbial growth on agar culture plates following incubation, replacing the manual reading step that has historically been performed by microbiologists in pharmaceutical and clinical laboratories. The technology was developed by microbiologists specifically for microbiology workflows and is supported by more than 25 peer-reviewed publications validating its clinical performance.
The company operates under the Clever Culture Systems commercial brand and sells a platform-plus-modules product architecture: the core APAS Independence instrument is complemented by Pharma Modules (for pharmaceutical environmental monitoring and quality control) and Clinical Modules (for urine screening, infection control, and antimicrobial susceptibility testing), plus Digital Reporting capabilities. Revenue is generated through capital-equipment sales of the APAS Independence instrument and recurring software/services streams tied to the installed base. The company pursues an enterprise field-sales go-to-market, with global headquarters in Adelaide, Australia, and direct sales and service offices in Irvine, California (USA) and Pfäffikon (Switzerland) to cover the global pharmaceutical and clinical laboratory markets.
LBT Innovations Limited firmographics
Firmographics- Name
- LBT Innovations Limited
- Legal name
- LBT Innovations Limited
- Website
- https://lbtinnovations.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- LBT Innovations Limited (ASX: LBT) designs AI-powered automated microbiology culture plate reading instruments (APAS Independence) for pharmaceutical environmental monitoring and clinical laboratories globally, commercialized under the Clever Culture Systems brand.
- Ownership category
- akta.pro rank
LBT Innovations Limited industry classification
Industry- Product category
- Microbiology Lab Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where LBT Innovations Limited is headquartered
LocationHeadquarters
- HQ city
- Adelaide
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
LBT Innovations Limited business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- APAS Independence Instrument Sales: Sale of the APAS Independence in-vitro diagnostic instrument to pharmaceutical and clinical laboratories. The instrument automates culture plate reading for microbiology labs.
- Software/Subscription Services: Ongoing software updates, maintenance, and support services for the APAS Independence system, likely delivered as recurring revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
LBT Innovations Limited product offering
Product offeringCore offering
LBT Innovations (commercially branded as Clever Culture Systems) designs, manufactures, and sells the APAS Independence, an AI-powered in-vitro diagnostic instrument that automates the imaging, interpretation, and reporting of microbial growth on agar culture plate media for pharmaceutical and clinical laboratories. The flagship instrument is complemented by dedicated Pharma Modules and Clinical Modules that apply the underlying AI platform to environmental monitoring and clinical diagnostics workflows respectively.
Product overview
Clever Culture Systems offers a platform-plus-modules architecture centered on the APAS Independence intelligent automated microbiology culture plate reading system. The core product (APAS Independence) provides automated imaging, analysis, and interpretation of agar culture plates using proprietary AI technology developed by microbiologists. This core platform is complemented by specialized modules: Pharma Modules for pharmaceutical environmental monitoring and quality control applications, and Clinical Modules for urine screening, infection control, and antimicrobial susceptibility testing. Additional features include Digital Reporting for enhanced result traceability. The system serves both pharmaceutical and clinical laboratory markets, functioning as an in-vitro diagnostic instrument for automated culture plate analysis.
Differentiator
Problem solved
Functional benefit
Brands
- APAS Independence: AI-powered intelligent automated microbiology culture plate reading technology that automates imaging, interpretation, and reporting of microbial growth on culture plate media for pharmaceutical and clinical laboratories.
Products and services
- APAS Independence An intelligent automated microbiology culture plate reading instrument that automates the imaging, interpretation, and reporting of microbial growth on agar culture plate media for pharmaceutical and clinical laboratories. It is an FDA-cleared in-vitro diagnostic instrument and the only scientifically proven instrument using artificial intelligence to read environmental monitoring culture plates following incubation.
- Pharma Modules AI-powered application modules tailored for pharmaceutical laboratory workflows, including environmental monitoring plate reading and quality control processes for pharmaceutical production environments. Sold as part of the APAS Independence platform offering.
- Clinical Modules AI-powered application modules tailored for clinical laboratory workflows, including urine screening for urinary tract infection, infection control, and antimicrobial susceptibility testing. Sold as part of the APAS Independence platform offering.
Companies that use LBT Innovations Limited
Customer profileSegments2 records
Ideal customer profiles2 records
LBT Innovations Limited technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
LBT Innovations Limited partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
LBT Innovations Limited competitors and assessment
Company assessmentBroad incumbents
- Becton, Dickinson and Company (BD): BD's Kiestra line is a leading automated microbiology specimen processing and incubation system for clinical labs. It is the most direct large-incumbent competitor to APAS Independence, with deep global installed bases and broader lab-automation portfolios.
- bioMérieux: bioMérieux is a global leader in clinical and industrial microbiology diagnostics, offering culture-based identification, AST, and lab automation. It competes across both pharma EM and clinical microbiology where APAS Independence is sold.
- Beckman Coulter (Danaher): Beckman Coulter provides clinical lab automation and diagnostics instrumentation. It is comparable to LBT as a broad lab-instrumentation incumbent with overlapping clinical microbiology customer relationships.
- Roche Diagnostics: Roche is a major clinical diagnostics player with microbiology and lab-automation offerings. Comparable to LBT as a large established vendor to clinical laboratories seeking workflow automation and standardized result reporting.
- Abbott Diagnostics: Abbott provides clinical diagnostics instruments and informatics to hospital and reference labs. It is comparable to LBT as an incumbent diagnostic platform vendor with overlapping clinical lab customer base and broader portfolio.
Direct peers
- Copan Diagnostics: Copan's WASPLab and WASP systems automate specimen processing and culture plate imaging for clinical microbiology labs. Like LBT, Copan targets culture-plate workflow automation and is a direct competitor in clinical lab AI plate reading.
Emerging players
- Accelerate Diagnostics: Accelerate Diagnostics offers rapid identification and antimicrobial susceptibility testing in clinical microbiology. Comparable to LBT as an emerging clinical-microbiology automation vendor, though it targets rapid molecular workflows rather than culture-plate AI.
- T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections. It is comparable to LBT as a smaller clinical-microbiology technology vendor competing for microbiology lab automation budgets.
- Selux Diagnostics: Selux Diagnostics is developing rapid AST systems for clinical microbiology labs. It overlaps with LBT's clinical microbiology customer base as a competing emerging automation and AST platform vendor.
Others
- Hamilton Company: Hamilton produces laboratory automation robots and workstations used in clinical and pharmaceutical labs. Comparable to LBT as an enabling lab-automation vendor that addresses similar workflow bottlenecks in pharma and clinical laboratories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
LBT Innovations Limited social profiles
Digital presenceLBT Innovations Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
LBT Innovations Limited leadership team
Management profileNumber of profiles
Profiles5 records
LBT Innovations Limited subsidiaries and ownership
Company hierarchySubsidiaries1 record
LBT Innovations Limited funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LBT Innovations Limited M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LBT Innovations Limited
What does LBT Innovations Limited do?
LBT Innovations (commercially branded as Clever Culture Systems) designs, manufactures, and sells the APAS Independence, an AI-powered in-vitro diagnostic instrument that automates the imaging, interpretation, and reporting of microbial growth on agar culture plate media for pharmaceutical and clinical laboratories. The flagship instrument is complemented by dedicated Pharma Modules and Clinical Modules that apply the underlying AI platform to environmental monitoring and clinical diagnostics workflows respectively.
Is LBT Innovations Limited a public or private company?
LBT Innovations Limited is a public company. It is classified as public and is currently operating.
When was LBT Innovations Limited founded?
LBT Innovations Limited was founded in 2012. It employs 11 to 50 people.
Where is LBT Innovations Limited based?
LBT Innovations Limited is headquartered in Adelaide, Australia, in the Oceania region.
How does LBT Innovations Limited make money?
Two revenue lines are on record. APAS Independence Instrument Sales are the primary driver. The others are software/Subscription Services.
Who are LBT Innovations Limited's main competitors?
Broad incumbents on record are Becton, Dickinson and Company (BD), bioMérieux, Beckman Coulter (Danaher), Roche Diagnostics and Abbott Diagnostics. Copan Diagnostics is listed as a direct peer. Emerging players are Accelerate Diagnostics, T2 Biosystems and Selux Diagnostics. Hamilton Company is listed as an others.
Does LBT Innovations Limited have an API?
No public API is recorded for LBT Innovations Limited.
What industry is LBT Innovations Limited in?
LBT Innovations Limited's product category is Microbiology Lab Instruments. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 334516 and its SIC code is 3826.